What is the appropriate treatment for a male patient with hidradenitis suppurativa, including a quarter‑size closed abscess on the right upper back and recurrent pustules, who was given selenium sulfide?

Selenium Sulfide Is Not Indicated for Hidradenitis Suppurativa

Selenium sulfide is FDA-approved exclusively for tinea versicolor, seborrheic dermatitis, and dandruff—not for hidradenitis suppurativa (HS)—and should be discontinued immediately in favor of evidence-based HS therapy. 1

Why Selenium Sulfide Is Inappropriate

• Selenium sulfide exerts a cytostatic effect on epidermal and follicular epithelial cells, reducing corneocyte production, which addresses superficial scaling conditions but has no role in the follicular occlusion and deep inflammatory pathology that defines HS. 1
• The FDA label explicitly contraindicates use when acute inflammation or exudation is present, because increased absorption may occur—precisely the clinical scenario in active HS with nodules, abscesses, and draining tunnels. 1
• No guideline from the American Academy of Dermatology, British Association of Dermatologists, or any HS consensus statement mentions selenium sulfide as a treatment option for HS at any Hurley stage. 2

Correct Evidence-Based Treatment for This Patient

Immediate First-Line Regimen for Moderate HS (Hurley Stage II)

• Initiate oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg once or twice daily for 10–12 weeks, which achieves response rates of 71–93% in patients with recurrent pustules and closed abscesses. 2
• Administer intralesional triamcinolone 10 mg/mL (0.2–2.0 mL) directly into the quarter-size closed abscess on the right upper back to provide rapid symptom relief within 24 hours, with significant reductions in erythema, edema, suppuration, and pain. 2
• Provide NSAIDs for analgesia and apply appropriate wound dressings to any draining lesions while the antibiotic regimen takes effect. 2

Treatment Duration and Monitoring

• Complete the full 10–12-week antibiotic course, then reassess disease activity using pain visual-analogue scale (VAS), inflammatory lesion count (nodules + abscesses), and Dermatology Life Quality Index (DLQI). 2
• After completing the course, institute a treatment break to evaluate the need for further therapy and to mitigate antimicrobial-resistance risk. 2

Escalation Pathway if First-Line Fails

• If no clinical response after 12 weeks of clindamycin-rifampicin, escalate to adalimumab 160 mg subcutaneously at week 0,80 mg at week 2, then 40 mg weekly starting at week 4, which achieves HiSCR response rates of 42–59% at week 12. 2
• For severe, widespread acute flares, a short course of oral prednisone may be used as bridge therapy while awaiting response to definitive treatments; this should be limited to the acute episode and not used for maintenance. 2

Mandatory Adjunctive Measures

• Refer for smoking-cessation services; 70–75% of HS patients are smokers, and tobacco use worsens outcomes. 2
• Provide weight-management counseling if BMI is elevated; obesity prevalence exceeds 75% in HS patients. 2
• Screen for depression, anxiety, and cardiovascular risk factors (blood pressure, lipid profile, HbA1c) because these comorbidities are highly prevalent in HS. 2

Critical Pitfalls to Avoid

• Do not continue selenium sulfide or any other non-evidence-based topical agent for HS; this delays appropriate systemic therapy and allows disease progression. 2
• Do not use doxycycline or tetracycline monotherapy as first-line for Hurley Stage II with abscesses, as these have minimal effect on deep inflammatory lesions (only ~30% abscess reduction). 2
• Do not extend antibiotic therapy beyond 12 weeks without formal reassessment, as prolonged use increases antimicrobial resistance without demonstrated additional benefit. 2